Evidence map›Paper›PMID 23336044›Full record

ReviewACS chemical neuroscience2013

A dialogue between the immune system and brain, spoken in the language of serotonin.

Nicole L Baganz, Randy D Blakely

Open access · greenAbstract readReview
In one paragraph

Review in ACS chemical neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 310 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nicole L BaganzDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-8548, United States.
Randy D Blakely
Vanderbilt University Medical Center · US

Funding

Stress-Mediated Alterations in Serotonin 2C Receptor Editing and FunctionP50MH096972 · NIMH · VANDERBILT UNIVERSITY · PI ZHANG, BING · 2012 to 2016
$10.5M
Program in NeurogenomicsT32MH065215 · NIMH · VANDERBILT UNIVERSITY · PI ROGER J COLBRAN · 2002 to 2026
$6.4M
Regulation of Serotonin TransportersR01MH094527 · NIMH · VANDERBILT UNIVERSITY · PI BLAKELY, RANDY D. · 2011 to 2021
$4.4M
Regulation of the presynaptic choline transporterF32MH078668 · NIMH · VANDERBILT UNIVERSITY · PI RUGGIERO, ALICIA M · 2007 to 2008
$103k
NIMH NIH HHS MH078668NIMH NIH HHS MH094527NIMH NIH HHS P50 MH096972NIMH NIH HHS R01 MH094527NIMH NIH HHS T32 MH065215
6 · The paper itself

Abstract

Neuropsychiatric disorders have long been linked to both immune system activation and alterations in serotonin (5-HT) signaling. In the CNS, the contributions of 5-HT modulate a broad range of targets, most notably, hypothalamic, limbic and cortical circuits linked to the control of mood and mood disorders. In the periphery, many are aware of the production and actions of 5-HT in the gut but are unaware that the molecule and its receptors are also present in the immune system where evidence suggests they contribute to the both innate and adaptive responses. In addition, there is clear evidence that the immune system communicates to the brain via both humoral and neuronal mechanisms, and that CNS 5-HT neurons are a direct or indirect target for these actions. Following a brief primer on the immune system, we describe our current understanding of the synthesis, release, and actions of 5-HT in modulating immune function, including the expression of 5-HT biosynthetic enzymes, receptors, and transporters that are typically studied with respect to the roles in the CNS. We then orient our presentation to recent findings that pro-inflammatory cytokines can modulate CNS 5-HT signaling, leading to a conceptualization that among the many roles of 5-HT in the body is an integrated physiological and behavioral response to inflammatory events and pathogens. From this perspective, altered 5-HT/immune conversations are likely to contribute to risk for neurobehavioral disorders historically linked to compromised 5-HT function or ameliorated by 5-HT targeted medications, including depression and anxiety disorders, obsessive-compulsive disorder (OCD), and autism. Our review raises the question as to whether genetic variation impacting 5-HT signaling genes may contribute to maladaptive behavior as much through perturbed immune system modulation as through altered brain mechanisms. Conversely, targeting the immune system for therapeutic development may provide an important opportunity to treat mental illness.

Indexed as

Adaptive ImmunityAnimalsAntidepressive AgentsBrainCytokinesHumansImmune SystemImmunity, InnateMental DisordersMiceMice, KnockoutSerotoninSerotonin Plasma Membrane Transport ProteinsSignal TransductionSynaptic TransmissionAntidepressive AgentsCytokinesSerotoninSerotonin Plasma Membrane Transport Proteins

Identifiers

PMID23336044
PMCPMC3547518
OpenAlexW2022461628

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.